MultiCell Technologies entered into a worldwide, exclusive license and technology purchase agreement with Corning related to its Fa2N-4 immortalized adult human liver cell lines.
Corning paid MultiCell a license fee and has agreed to purchase certain inventory and equipment linked to this business, hire some of MultiCell’s scientific personnel, and pay for access to its laboratories during transfer of the cell lines.
MultiCell will retain and continue to support all of its existing licensees. It retains the right to use the Fa2N-4 cells for applications not related to drug discovery or ADME/Tox assays. It may also apply these cell lines to develop its Sybiol® liver assist device, to produce therapeutic proteins, to identify drug targets, and for other processes related to the company's internal drug development programs.
“We are pleased to partner with Corning in the drug discovery assay tools, ADME/Tox, and biomarker segments,” says Jerry Newmin, chairman of MultiCell’s board. “MultiCell's focus is on using our therapeutic antibody and Toll-like receptor technologies to develop new drug candidates and to advance our lead drug candidate, MCT-125, for the treatment of primary MS-related fatigue.